Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;144(1):157-163.
doi: 10.1007/s00432-017-2530-3. Epub 2017 Oct 9.

Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety

Jia-Yan Ni  1 , Hong-Liang Sun  1 , Yao-Ting Chen  1 , Jiang-Hong Luo  1 , Wei-Dong Wang  1 , Xiong-Ying Jiang  1 , Dong Chen  1 , Lin-Feng Xu  2
Affiliations

Drug-eluting bead transarterial chemoembolization in the treatment for unresectable soft tissue sarcoma refractory to systemic chemotherapy: a preliminary evaluation of efficacy and safety

Jia-Yan Ni et al. J Cancer Res Clin Oncol. 2018 Jan.

Abstract

Purpose: To preliminarily evaluate the clinical efficacy and safety of drug-eluting bead transarterial chemoembolization (DEB-TACE) for unresectable soft tissue sarcoma refractory to systemic chemotherapy.

Methods: Ten patients with refractory sarcoma who underwent DEB-TACE therapy between January 2015 and January 2017 were identified. Clinical information and radiological data were retrospectively collected to analyze tumor response, overall survival (OS), progression-free survival and adverse events (AEs). Tumor response to DEB-TACE was assessed with modified Response Evaluation Criteria in Solid Tumors (mRECIST) guidelines applied to computed tomography or magnetic resonance imaging.

Results: All DEB-TACE procedures were successfully performed for ten patients with 15 tumor lesions. The median follow-up duration was 19 months and the median survival time was 21 months (range 11-30 months). The 1- and 2-year OS rate was 90 and 30%, respectively. According to the guidance of mRECIST, complete response, partial response, stable disease and progressive disease were noted in zero (0%), three (30%), four (40%) and three (30%) patients, respectively. The disease control rate and objective response rate was 70 and 30%, respectively. There were no serious AEs in patients after DEB-TACE.

Conclusions: Our data showed that DEB-TACE was effective and safe for patients with soft tissue sarcoma. Therefore, DEB-TACE can be considered as an alternative treatment option for unresectable soft tissue sarcoma refractory to conventionally systemic chemotherapy.

Keywords: Drug-eluting bead; Soft tissue sarcoma; Systemic chemotherapy; Transarterial chemoembolization.

PubMed Disclaimer

Conflict of interest statement

We declare that we have no conflict of interest.

Figures

Fig. 1
Fig. 1
Kaplan–Meier curve shows overall survival rates for patients who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment
Fig. 2
Fig. 2
Kaplan–Meier curve shows progression-free survival rates for patients who underwent drug-eluting bead transarterial chemoembolization (DEB-TACE) treatment
Fig. 3
Fig. 3
Representative pictures of pre-DEB-TACE (a, b) and post-DEB-TACE (f) CT scans and pre-DEB-TACE (d) and post-DEB-TACE (e) angiographies of a 38-year-old female patient with histologically established (c) synovial sarcoma. Post-DEB-TACE images (e, f) show reduced tumor staining and tumor size. (a is non contrast-enhanced CT scan which shows the pathological calcification inside the rumor lesion. DEB-TACE drug-eluting bead transarterial chemoembolization)
See this image and copyright information in PMC

References

    1. Chawla SP, Papai Z, Mukhametshina G et al (2015) First-line aldoxorubicin vs doxorubicin in metastatic or locally advanced unresectable soft-tissue sarcoma: a phase 2b randomized clinical trial. JAMA Oncol 1:1272–1280 - PubMed
    1. Chegai F, Orlacchio A, Merolla S et al (2015) Intermediate hepatocellular carcinoma: the role of transarterial therapy. Hepat Oncol 2:399–408 - PMC - PubMed
    1. Constantinidou A, van der Graaf WTA (2017) The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer 84:257–261 - PubMed
    1. Currie BM, Soulen MC (2017) Decision making: intra-arterial therapies for cholangiocarcinoma-TACE and TARE. Semin Intervent Radiol 34:92–100 - PMC - PubMed
    1. Facciorusso A, Mariani L, Sposito C et al (2016) Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol 31:645–653 - PubMed

LinkOut - more resources